health 🔬 CAR T therapy company gearing up for big trial
A CAR T-cell therapy company is preparing to advance to a pivotal Phase III clinical trial using donor cells. This company, Caribou Biosciences, is making strides in making allogeneic CAR T therapies as effective as autologous ones. They achieved this using gene editing and optimizing product selection, including using donors under 30. This off-the-shelf approach aims to solve access issues, as 75 to 90% of eligible patients currently do not receive CAR T. They plan to start their randomized-controlled Phase III study in the coming months for their product, vispa-cel. 🔬